Results of the cell study, published in Research and Reports in Urology,indicated that Euromed’s Prosterol saw palmetto extract could inhibit 5alpha-reductase, an enzyme that is the target of pharmaceuticals such as finasteride to treat enlarged prostate or benign prostate hyperplasia (BPH).
The data indicated that the Prosterol ingredient was as effective as both a saw palmetto extract made with the solvent hexane and finasteride.
“It can be confirmed from the results of this study that the [saw palmetto supercritical CO2 extract] Prosterol has bioactivity that promotes prostate health at a level that is superior to that of many other phytotherapeutic extracts,” wrote the researchers.
“The bioactivity of Prosterol corresponds favorably to that reported for the hexane extract used in a large number of positive BPH clinical trials, as well as to finasteride, the established standard of therapy among prescription drugs. By establishing the bioactivity of [saw palmetto supercritical CO2 extract], the present study reinforces the importance of conducting such trials prior to attempting clinical studies.
“Confirming bioactivity increases the likelihood of showing positive effects clinically, while reducing the chances of negative studies, such as those reported in the literature. Future in vitro and clinical trials involving [saw palmetto extracts] would be useful for elucidating their comparative differences as well as appropriate patient selection for their use.”
Euromed scientists performed the study and the company funded the research.
Source: Research and Reports in Urology
Volume 2016:8 Pages 41-44
“Determination of the potency of a novel saw palmetto supercritical CO2 extract (SPSE) for 5α-reductase isoform II inhibition using a cell-free in vitro test system”
Authors: P. Pais et al